Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny subsequently
Immigrated to America, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical themes, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
After authoring seven papers during a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published a
Lot of experimental research papers and theoretical papers as sole
Author. These sole-author publications
Discussed two crucial topics.
The first of those mentioned selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Confirming their resistance. The outcomes and underlying
Notion were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the article was
Titled, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
The second theme throughout Dr. Blagosklonny’s sole-author works
Is a research methodology to produce knowledge via
Bringing a few facts together from seemingly unrelated areas.
This results in new concepts containing testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable result discovered by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others can’t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Stopping organism aging — in other words, “preventing cancer
By staying young. ” His laboratory closely worked together with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging
Medications besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including a few models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Prolongation and cancer cure in mice, and combinations of anti-
Aging drugs to be used in humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.